Recurrent Clostridioides difficile infection (CDI) is a major clinical problem, and the optimal antimicrobial regimen to prevent recurrence after a first episode or first recurrence remains uncertain. Emerging interest has focused on pulse‑and‑taper (P‑T) dosing strategies as well as comparisons between fidaxomicin and vancomycin. The authors performed a systematic review and network meta‑analysis of randomized controlled trials (RCTs) to estimate the relative efficacy of fixed‑dose and P‑T regimens of fidaxomicin and vancomycin for preventing recurrent CDI.
The investigators searched MEDLINE and the Cochrane CENTRAL database from inception through May 21, 2025 and reviewed unpublished abstracts from recent infectious disease conferences. Eligible studies were randomized controlled trials that evaluated treatment of first CDI episodes or first recurrences and compared fixed‑dose (standard 10–14 days) or pulse‑and‑taper regimens of fidaxomicin or vancomycin. The primary outcome was CDI recurrence at 40 days; a secondary outcome was recurrence at 56 days. The analytic approach was a random‑effects network meta‑analysis on the risk ratio (RR) scale using standard 10–14 day vancomycin as the reference comparator. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA).
Eight randomized controlled trials met inclusion criteria, comprising a total of 2,181 patients. Trials addressed treatment of initial episodes and first recurrences; the source report did not provide trial‑level identifiers or additional baseline details in the abstracted material presented here.
For the primary outcome of recurrence at 40 days, treatment effect estimates from the network meta‑analysis favored fidaxomicin and P‑T regimens over standard fixed‑dose vancomycin. Reported comparative results were:
Fidaxomicin pulse‑and‑taper: RR = 0.10 (95% Confidence Interval [95% CI] = 0.10–0.49); SUCRA = 1.00. This regimen had the highest probability of being the most effective for preventing 40‑day recurrence.
Vancomycin pulse‑and‑taper: RR = 0.49 (95% CI = 0.32–0.76); SUCRA = 0.61. This P‑T vancomycin strategy reduced 40‑day recurrence compared with standard 10–14 day vancomycin.
Fixed‑dose fidaxomicin: RR = 0.61 (95% CI = 0.49–0.76); SUCRA = 0.39. Fixed‑dose fidaxomicin was superior to fixed‑dose vancomycin but ranked below the P‑T approaches.
Fixed‑dose vancomycin: SUCRA = 0.00 and served as the network reference; it ranked lowest for preventing 40‑day recurrence.
These estimates indicate lower risks of short‑term recurrence with fidaxomicin—particularly with a pulse‑and‑taper approach—and with vancomycin when administered as a P‑T regimen, relative to standard fixed‑dose vancomycin.
The reported ranking order for 56‑day recurrence matched that for 40 days (fidaxomicin P‑T highest, followed by vancomycin P‑T, fixed‑dose fidaxomicin, and fixed‑dose vancomycin). However, only three RCTs contributed data to the 56‑day timepoint. The source article indicates the same ordering but does not present additional numeric effect estimates for the 56‑day outcome in the abstracted material.
Treatment rankings by SUCRA for the 40‑day endpoint were as follows: fidaxomicin pulse‑and‑taper (SUCRA 1.00), vancomycin pulse‑and‑taper (SUCRA 0.61), fixed‑dose fidaxomicin (SUCRA 0.39), and fixed‑dose vancomycin (SUCRA 0.00). The SUCRA ordering was the same for the 56‑day analyses, though with fewer contributing trials.
In this preprint network meta‑analysis of 8 RCTs including 2,181 patients, P‑T regimens and fidaxomicin were associated with lower short‑term recurrence of CDI compared with a standard 10–14 day vancomycin regimen. Specifically, fidaxomicin P‑T had the highest estimated probability of preventing 40‑day recurrence. The authors conclude that vancomycin P‑T, fidaxomicin P‑T, and fixed‑dose fidaxomicin were each superior to fixed‑dose vancomycin. They emphasize the need for direct head‑to‑head randomized trials to better quantify relative effect sizes and to evaluate long‑term prevention of recurrent CDI.
This report is a preprint and has not been peer reviewed; readers should interpret findings accordingly. Only eight RCTs were included and the 56‑day recurrence outcome was reported by just three trials, limiting precision for longer follow‑up. Trial‑level details, safety outcomes, and cost or resource implications were not provided in the abstracted material. The authors call for head‑to‑head comparative effectiveness RCTs to confirm and quantify the relative benefits of P‑T versus fixed‑dose regimens and to assess their impact on longer‑term recurrence prevention.